- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
PAREXEL Introduces New Dedicated Division to Help Emerging Biotech Companies Reach their Goals Quickly and Cost-Effectively
PAREXEL, an innovator of global biopharmaceutical services, introduced a new, dedicated division to support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.
PAREXEL Biotech combines the company’s expertise and global infrastructure with a model that is aligned to this specific segment, providing enhanced consulting and development capabilities through a new biotech-focused team and organizational structure. This team led by James Anthony and Graciela Racaro, will help emerging companies minimize complexity, reduce costs, and accelerate timelines through the use of many different strategies and services. Those services and strategies include global regulatory consulting, patient recruitment services, trial execution services, Real World Evidence programs, and much more.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.
